נולוג'יקס 250 מ"ג

Negara: Israel

Bahasa: Ibrani

Sumber: Ministry of Health

Bahan aktif:

BELATACEPT 25 MG/ML

Tersedia dari:

BRISTOL-MYERS SQUIBB (ISRAEL) LIMITED

Kode ATC:

L04AA28

Bentuk farmasi:

POWDER FOR CONCENTRATE FOR INFUSION

Rute administrasi :

I.V

Diproduksi oleh:

BRISTOL-MYERS SQUIBB S.R.L, ITALY

Kelompok Terapi:

BELATACEPT

Indikasi Terapi:

Nulojix, in combination with corticosteroids and mycophenolic acid (MPA), is indicated for prophylaxis of graft rejection in adults receiving a renal transplant. It is recommended to add an interleukin (IL)-2 receptor antagonist for induction therapy to this belatacept-based regimen

Tanggal Otorisasi:

2012-08-01